Nebenwirkungen · Steglatro
Steglatro 5 mg film-coated tablets Steglatro 15 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 8
HOS-137641 · Präparat HOS-098083
Pool of placebo-controlled trials evaluating Steglatro 5 mg and 15 mg The primary assessment of safety was conducted in a pool of three 26-week, placebo-controlled trials. Ertugliflozin was used as monotherapy in one trial and as add-on therapy in two trials (see section 5.1). These data reflect exposure of 1 029 patients to ertugliflozin with a mean exposure duration of approximately 25 weeks. Patients received ertugliflozin 5 mg (N=519), ertugliflozin 15 mg (N=510), or placebo (N=515) once daily.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-21T02:00:00Z · SHA-256 5baeb717396c9983a8fe8fdd9275ddd5dee36f5f706f04ce7ca090a915f2b671 · Passage 385e83dd07365757f6adda37a04c072697e183e642baebc18f3c7b459df3adb3 · Zeichen 557–1060 im Abschnitt